• Aptevo appointed Mary J. Janatpour as senior vice president, chief scientific officer to lead research, preclinical development, pipeline strategy.
• She brings over 25 years of oncology R&D leadership across biotech, pharma, spanning target discovery, translational science, immuno-oncology.
• Previously held leadership roles at Novartis Institutes for Biomedical Research, Schering-Plough Biopharma, Chiron, focused on oncology biologics targets.
• Appointment supports a clinical focus on mipletamig, an expanding multispecific oncology pipeline, a radiopharmaceutical strategy tied to Niowave collaboration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605280805ACCESSWRNAPR_____1171339) on May 28, 2026, and is solely responsible for the information contained therein.